[1]李燃,张万增,赵庚水.脑膜瘤的临床治疗进展[J].中国临床神经外科杂志,2024,29(07):442-445.[doi:10.13798/j.issn.1009-153X.2024.07.013]
　LI Ran,ZHANG Wan-zeng,ZHAO Geng-shui.Clinical treatment progress of meningiomas[J].,2024,29(07):442-445.[doi:10.13798/j.issn.1009-153X.2024.07.013]
点击复制

脑膜瘤的临床治疗进展()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
29
期数:
2024年07期
页码:
442-445
栏目:
综述
出版日期:
2024-07-30

文章信息/Info

Title:
Clinical treatment progress of meningiomas
文章编号:
1009-153X（2024）07-0442-04
作者:
李燃; 张万增; 赵庚水
053000河北衡水，哈励逊国际和平医院神经外科（李燃、张万增、赵庚水）
Author(s):
LI Ran;  ZHANG Wan-zeng;  ZHAO Geng-shui
Department of Neurosurgery, Harrison International Peace Hospital, Hengshui 053000, China
关键词:
脑膜瘤; 分子特征; 手术治疗; 靶向治疗
Keywords:
Meningioma;  Molecular characteristics;  Surgical treatment;  Targeted therapy
分类号:
R 739.41
DOI:
10.13798/j.issn.1009-153X.2024.07.013
文献标志码:
A
摘要:
脑膜瘤是中枢神经系统常见的原发性肿瘤。根据世界卫生组织（WHO）2016年组织学标准，大多数脑膜瘤为良性（WHO分级Ⅰ级），5％~7%为非典型脑膜瘤，3%为间变性脑膜瘤。目前，脑膜瘤主要采用随访观察和手术治疗；对非典型和间变性脑膜瘤，可辅助放化疗；颅底脑膜瘤常涉及血管神经结构，手术难度大；复发性肿瘤以放疗和再次手术为主。基于NF2、SMO、TERT、TRAF7等基因突变和甲基化谱的肿瘤分子特征的靶向治疗有道进一步研究。本文根据国际指南和最近的文献介绍当前的标准治疗方法，并描述了为治疗复杂脑膜瘤而开展的新技术。
Abstract:
Meningiomas are common primary tumors in the central nervous system. According to the histological criteria of the World Health Organization (WHO) in 2016, the majority of meningiomas are benign (WHO grade Ⅰ), 5%~7% are atypical meningiomas, and 3% are anaplastic meningiomas. Currently, meningiomas are mainly treated with follow-up observation and surgical treatment; for atypical and anaplastic meningiomas, adjuvant radiotherapy and chemotherapy can be applied; skull base meningiomas often involve vascular and neural structures, resulting in high surgical difficulty; recurrent tumors are mainly treated with radiotherapy and reoperation. Targeted therapy based on tumor molecular characteristics such as gene mutations of NF2, SMO, TERT, TRAF7 and methylation profiles is under further investigation. This article introduces the current standard treatment methods based on international guidelines and the latest literature, and describes the new technologies developed for the treatment of complex meningiomas.

参考文献/References:

[1]LOUIS DN, PERRY A, WESSELING P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary[J]. Neuro Oncol, 2021, 23(8): 1231-1251.
[2]GRITSCH S, BATCHELOR TT, GONZALEZ CASTRO LN. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system[J]. Cancer, 2022, 128(1): 47-58.
[3]LOUIS DN, PERRY A, REIFENBERGER G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary[J]. Acta Neuropathol, 2016, 131(6): 803-820.
[4]CHOUDHURY A, MAGILL ST, EATON CD, et al. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities[J]. Nat Genet, 2022, 54(5): 649-659.
[5]MARINCEK N, RADOJEWSKI P, DUMONT RA, et al. Somatostatin receptor-targeted radiopeptide therapy with 90 Y-DOTATOC and 177 Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial[J]. J Nucl Med, 2015, 56(2): 171-176.
[6]GRAILLON T, SANSON M, CAMPELLO C, et al. Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial[J]. Clin Cancer Res, 2020, 26(3): 552-557.
[7]GRAILLON T, FERRER L, SIFRE J, et al. Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study[J]. Neuro Oncol, 2021, 23(7): 1139-1147.
[8]SHARMA R, GARG K, KATIYAR V, et al. The role of mifepristone in the management of meningiomas: a systematic review of literature [J]. Neurol India, 2019, 67(3): 698-705.
[9]PISTOLESI S, BOLDRINI L, GISFREDI S, et al. Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study: angiogenesis in meningiomas[J]. Neuropathol Appl Neurobiol, 2004, 30(2): 118-125.
[10]KALEY TJ, WEN P, SCHIF D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma[J]. Neuro Oncol, 2015, 17(1): 116-121.
[11]KALEY T, BARANI I, CHAMBERLAIN M, et al. Historical benchmarks for medical therapy trials in surgery-and radiation-refractory meningioma: a RANO review[J]. Neuro Oncol, 2014, 16(6): 829-840.
[12]NAYAK L, IWAMOTO FM, RUDNICK JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab[J]. J Neurooncol, 2012, 109(1): 187-193.
[13]ZENG Q, TIAN Z, GAO Q, et al. Effectiveness of postoperative radiotherapy in patients with atypical meningiomas after gross total resection: analysis of 260 cases[J]. World Neurosurg, 2022, 162: e580-e586.
[14]KIM RB, FREDRICKSON VL, COULDWELL WT. Visual outcomes in spheno-orbital meningioma: a 10-year experience[J]. World Neurosurg, 2022, 158: e726-e734.
[15]NANGARWAL B, GOSAL JS, DAS KK, et al. Anterior skull base meningioma: surgical approach and complication avoidance[J]. J Neurol Surg B Skull Base, 2022, 84(1): 38-50.
[16]WAGNER A, ALRAUN M, KAHLIG V, et al. Surgical and functional outcome after resection of 64 petroclival meningiomas[J]. Cancers (Basel), 2022, 14(18): 4517-4531.
[17]MAGILL ST, SCHWARTZ TH, COULDWELL WT, et al. International tuberculum sellae meningioma study: surgical outcomes and management trends[J]. Neurosurgery, 2023, 93(6): 1259-1270.
[18]PARK GO, PARK HH, YOO J, et al. Surgical outcomes of sphenoid wing meningioma with periorbital invasion[J]. J Korean Neurosurg Soc, 2022, 65(3): 449-456.
[19]CHAMBERLAIN MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma[J]. J Neurooncol, 2012, 107 (2): 315-321.
[20]LOVEN D, HARDOF R, SEVER ZB, et al. Non-resectable slow-growing meningiomas treated by hydroxyurea[J]. J Neurooncol, 2020, 67(1-2): 221-226.
[21]MASON WP, GENTILI F, MACDONALD DR, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningiomas[J]. J Neurosurg, 2020, 97(2): 341-346.
[22]CHAMBERLAIN MC, TSAO-WEI DD, GROSHEN S. Salvage chemotherapy with CPT-11 for recurrent meningioma[J]. J Neurooncol, 2006, 78(3): 271-276.
[23]BELANGER K, UNG TH, DAMEK D, et al. Concomitant temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review[J]. BMC Cancer, 2022, 22(1): 367-372.
[24]CHAMBERLAIN MC, TSAO-WEI DD, GROSHEN S. Temozolomide for treatment-resistant recurrent meningioma[J]. Neurology, 2004, 62(7): 1210-1212.
[25]CHAMBERLAIN MC. Adjuvant combined modality therapy for malignant meningiomas[J]. J Neurosurg, 1996, 84(5): 733-736.
[26]JOHNSON DR, KIMMEL DW, BURCH PA, et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma[J]. Neuro Oncol, 2011, 13(5): 530-535.
[27]NORDEN AD, LIGON KL, HAMMOND SN, et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma[J]. Neurology, 2015, 84(30): 280-286.
[28]SIM M, ARGYRIOU AA, MACI M, et al. Recurrent highgrade meningioma: a phase II trial with somatostatin analogue therapy[J]. Cancer Chemother Pharmacol, 2014, 73(5): 919-923.
[29]BRASTIANOS PK, HOROWITZ PM, SANTAGATA S, et al. Genomic sequencing of meningiomas identifes oncogenic SMO and AKT1 mutations[J]. Nat Genet, 2020, 45(3): 285-289.
[30]YOUNG JS, KIDWELL RL, ZHENG A, et al. CDK 4/6 inhibitors for the treatment of meningioma[J]. Front Oncol, 2022, 12(7): 931371.
[31]LARABA L, HILLSON L, DE GUIBERT JG, et al. Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma[J]. Brain, 2023, 146(4): 1697-1713.
[32]BRASTIANOS PK, TWOHY E, GERSTNER ER, et al. Alliance A071401: phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations[J]. J Clin Oncol, 2023, 41(3): 618-628.
[33]CLARK VE, ERSON-OMAY EZ, SERIN A, et al. Genomic analysis of Non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO[J]. Science, 2013, 339(6123): 1077-1080.
[34]PREUSSER M, BRASTIANOS PK, MAWRIN C. Advances in meningioma genetics: novel therapeutic opportunities[J]. Nat Rev Neurol, 2018, 14(2): 106-115.
[35]SPRECKELSEN NV, WALDT N, POETSCHKE R, et al. KLF4K-409Q-mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment[J]. Acta Neuropathol Commun, 2020, 8(1): 41-51.
[36]ABEDALTHAGAF M, BI WL, AIZER AA, et al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma[J]. Neuro Oncol, 2016, 18(5): 649-655.
[37]SAHM F, SCHRIMPF D, STICHEL D, et al. DNA methylationbased classification and grading system for meningioma: a multi-centre, retrospective analysis[J]. Lancet Oncol, 2017, 18(5): 682-694.
[38]OLAR A, WANI KM, WILSON CD, et al. Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma[J]. Acta Neuropathol, 2017, 133(3): 431-444.

相似文献/References:

[1]李春坡　郑　军　李海元　边　涛　韩安国.侧脑室三角区小型脑膜瘤的显微外科治疗[J].中国临床神经外科杂志,2015,(11):694.[doi:10.13798/j.issn.1009-153X.2015.11.018]
[2]王林风　郑华山　操　廉.中央沟区矢状窦旁脑膜瘤的显微手术治疗（附25例报告）[J].中国临床神经外科杂志,2016,(07):431.[doi:10.13798/j.issn.1009-153X.2016.07.014]
[3]邓学云　刘　毅　范润金　刘丽华　夏祥国.E-cadherin与脑膜瘤分级及瘤周水肿的关系[J].中国临床神经外科杂志,2016,(04):213.[doi:10.13798/j.issn.1009-153X.2016.04.007]
　DENG Xue-yun,LIU Yi,FAN Run-jin,et al.Relationship of E-cadherin with the pathological grade of meningioma and peritumoral brain edema in patients with meningioma[J].,2016,(07):213.[doi:10.13798/j.issn.1009-153X.2016.04.007]
[4]马　磊　张海红　郭　康　孙树凯　张　亮　贾　栋.神经导航辅助下手术治疗侧脑室脑膜瘤1例[J].中国临床神经外科杂志,2016,(04):255.[doi:10.13798/j.issn.1009-153X.2016.04.023]
[5]王　一　崔焕喜　林令超　孙思辉　李绍山　周庆九　刘　波　柳　琛.侧脑室三角区脑膜瘤的显微手术治疗[J].中国临床神经外科杂志,2016,(03):161.[doi:10.13798/j.issn.1009-153X.2016.03.010]
　WANG Yi,CUI Huan-xi,LIN Ling-chao,et al.Microsurgery for meningiomas in the trigones of lateral ventricles (report of 47 cases)[J].,2016,(07):161.[doi:10.13798/j.issn.1009-153X.2016.03.010]
[6]王　鹏 综述　王　勇 审校.岩斜区脑膜瘤的手术入路[J].中国临床神经外科杂志,2016,(02):120.[doi:10.13798/j.issn.1009-153X.2016.02.024]
[7]漆松涛　刘　忆.关于WHO2007年版脑膜瘤病理分类一些问题的商榷[J].中国临床神经外科杂志,2016,(02):125.[doi:10.13798/j.issn.1009-153X.2016.02.026]
[8]李登辉　程　荆　李志强.镰旁脑膜瘤术后并发格林巴利综合征1例[J].中国临床神经外科杂志,2016,(02):72.[doi:10.13798/j.issn.1009-153X.2016.02.003]
[9]肖宗宇　陈晓娟　裴　杰　贺瑛福　许常林　马进海.超声吸引器在脑膜瘤手术切除中的应用[J].中国临床神经外科杂志,2015,(10):626.[doi:10.13798/j.issn.1009-153X.2015.10.016]
[10]杨　俊　吴雪松　莫鸿忠　潘荣南　赖　杰.双源CT三维血管成像技术在脑膜瘤术前评估中的应用[J].中国临床神经外科杂志,2015,(06):347.[doi:10.13798/j.issn.1009-153X.2015.06.009]
　YANG Jun,WU Xue-song,MO Hong-zhong,et al.Application of three-dimensional dual-source CT angiography to preoperative assessment of meningiomas[J].,2015,(07):347.[doi:10.13798/j.issn.1009-153X.2015.06.009]

备注/Memo

备注/Memo:
（2023-08-09收稿，2023-12-11修回）
更新日期/Last Update: 2024-07-30